4-(1-Azabicyclo[2.2.2]octan-3-yl)-6-bromo-1-(difluoromethyl)indazole-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 4-(1-Azabicyclo[2.2.2]octan-3-yl)-6-bromo-1-(difluoromethyl)indazole-3-carboxamide
• 英文别名: 4-(1-azabicyclo[2.2.2]octan-3-yl)-6-bromo-1-(difluoromethyl)indazole-3-carboxamide
• 化学式: C₁₆H₁₇BrF₂N₄O
• 分子量: 399.23
• InChiKey: UTRZZNKBUUOHTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 5HT3 RECEPTOR ANTAGONISTS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2875012A1

  公开（公告）日：2015-05-27
• [EN] 5HT3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR 5HT3
  申请人：ENVOY THERAPEUTICS INC

  公开号：WO2014014962A1

  公开（公告）日：2014-01-23

  The present invention provides compounds of the formula: (I) that are 5HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.